AG
MTNB icon

Advisor Group’s Matinas BioPharma MTNB Stock Holding History

Advisor Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$9K Hold
80
– – ﹤0.01% 4421
2019
Q3 		$3K Hold
80
– – ﹤0.01% 4851
2019
Q2 		$3K Hold
80
– – ﹤0.01% 4872
2019
Q1 		$4K Buy
+80
New +$4.31K ﹤0.01% 4773

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Advisor Group's MTNB Position: Q4 2019 in Review

Advisor Group held its Matinas BioPharma (MTNB) position steady in Q4 2019 at 80 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #4421.

Advisor Group first reported a position in MTNB in Q1 2019 and has held it in 4 quarters since. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2019.

  • Advisor Group held 80 shares of Matinas BioPharma worth $9K as of Q4 2019.
  • Advisor Group left its Matinas BioPharma share count unchanged in Q4 2019.
  • Matinas BioPharma made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4421 holding.
  • Advisor Group first reported a position in Matinas BioPharma in Q1 2019 and has held it in 4 quarters since.
  • 64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.